SCHEMBL3539844

SCHEMBL3539844

CCOC(=O)C1CCCc2sc(NC(=N)N)nc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.44
ALDH1A1 P00352 7/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 5/20 0.38
GAA P10253 5/20 0.38
HSD17B10 Q99714 2/20 0.38
RECQL P46063 1/20 0.38
TSHR P16473 2/20 0.36
PDK1 Q15118 1/20 0.35
HPGD P15428 4/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
XIAP P98170 2/20 0.34
LIMK1 P53667 1/20 0.34
DHODH Q02127 1/20 0.34
POLB P06746 2/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13314787 1.00 PARP1 (0.44) PARP1ALDH1A1MEN1KMT2ASMN1; SMN2
Bromide SCHEMBL3536459 0.99 PARP1 (0.43) PARP1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL6210046 0.83 PARP1 (0.40) PARP1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL13314778 0.83 PARP1 (0.45) PARP1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4807243 0.83 PARP1 (0.47) PARP1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3536953 0.82 XIAP (0.36) PARP1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4806056 0.82 PARP1 (0.47) PARP1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL999312 0.82 PARP1 (0.42) PARP1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3537156 0.81 PARP1 (0.47) PARP1ALDH1A1SMN1; SMN2KDM4EGAA
SCHEMBL3542684 0.81 XIAP (0.37) PARP1ALDH1A1SMN1; SMN2KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060194788-A1 Guanidine derivatives and their use as neuropeptide ff receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2006-08-31 US claimed
US-20150246140-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2015-09-03 US disclosed
WO-2015120446-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULENESS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2015-08-13 WO disclosed
US-7727979-B2 Guanidine derivatives and their use as neuropeptide FF receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2010-06-01 US disclosed
US-20060194788-A1 Guanidine derivatives and their use as neuropeptide ff receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194788-A1 Guanidine derivatives and their use as neuropeptide ff receptor antagonists NPFFR1, OGFR, NPFFR2 PARP1 2737/4885ALDH1A1 1895/4885MEN1 4157/4885
US-20150246140-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS HCRTR2, HCRTR1, NPSR1 PARP1 3588/4885ALDH1A1 4570/4885MEN1 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.